Rett Syndrome: Reaching for Clinical Trials

Neurotherapeutics

Volumn 12, Issue 3, 2015, Pages 631-640

  Pozzo Miller, Lucas ^a   Pati, Sandipan ^b   Percy, Alan K ^c  

^a University of Alabama at Birmingham   (United States)

^b University of Alabama at Birmingham   (United States)

^c University of Alabama at Birmingham and Children's Hospital   (United States)

Author keywords

Clinical trials; Drug targets; MECP2; Rare disease; Rett syndrome; X linked dominant

Indexed keywords

4 AMINOBUTYRIC ACID; ANTIBIOTIC G 418; BRAIN DERIVED NEUROTROPHIC FACTOR; DESIPRAMINE; DEXTROMETHORPHAN; FINGOLIMOD; GENTAMICIN; GLATIRAMER; GLUTAMIC ACID; METHYL CPG BINDING PROTEIN 2; MONOAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NLX 101; RECOMBINANT SOMATOMEDIN C; SARIZOTAN; SEROTONIN AGONIST; SOMATOMEDIN C; TROFINETIDE; UNCLASSIFIED DRUG; VATIQUINONE; VIGABATRIN; MECP2 PROTEIN, HUMAN; MECP2 PROTEIN, MOUSE;

ACTIMETRY; BREATH HOLDING; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); CONSTIPATION; ELECTROENCEPHALOGRAPHY; EPILEPSY; GASTROESOPHAGEAL REFLUX; GENE THERAPY; GROWTH DISORDER; HEAD CIRCUMFERENCE; HUMAN; HYPERVENTILATION; IN VIVO GENE TRANSFER; INTRACELLULAR SIGNALING; LOSS OF FUNCTION MUTATION; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; MUSCLE TONE; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; RETT SYNDROME; REVIEW; SCOLIOSIS; X CHROMOSOME INACTIVATION; ANIMAL; AUTISM SPECTRUM DISORDER; BRAIN; DISEASE MODEL; GENETICS; METABOLISM; MOUSE; MUTATION; NERVE CELL; PATHOLOGY;

ANIMALS; AUTISM SPECTRUM DISORDER; BRAIN; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; HUMANS; METHYL-CPG-BINDING PROTEIN 2; MICE; MUTATION; NEURONS; RETT SYNDROME;

EID: 84937631474     PISSN: 19337213     EISSN: 18787479     Source Type: Journal    
DOI: 10.1007/s13311-015-0353-y     Document Type: Review

References (112)

1. Rett A. [On a unusual brain atrophy syndrome in hyperammonemia in childhood]. Wien Med Wochenschr 1966;116:723-726.
2. Hagberg B, Aicardi J, Dias K, Ramos O. A progressive syndrome of autism, dementia, ataxia, and loss of purposeful hand use in girls: Rett's syndrome: report of 35 cases. Ann Neurol 1983;14:471-479.
3. Hagberg B, Goutieres F, Hanefeld F, Rett A, Wilson J. Rett syndrome: criteria for inclusion and exclusion. Brain Dev 1985;7:372-373.
4. Diagnostic criteria for Rett syndrome. The Rett Syndrome Diagnostic Criteria Work Group. Ann Neurol 1988;23:425-428.
5. Hagberg B, Hanefeld F, Percy A, Skjeldal O. An update on clinically applicable diagnostic criteria in Rett syndrome. Comments to Rett Syndrome Clinical Criteria Consensus Panel Satellite to European Paediatric Neurology Society Meeting, Baden Baden, Germany, 11 September 2001. Eur J Paediatr Neurol 2002;6:293-297.
6. Neul JL, Kaufmann WE, Glaze DG, et al. Rett syndrome: revised diagnostic criteria and nomenclature. Ann Neurol 2010;68:944-950.
7. Percy AK, Neul JL, Glaze DG, et al. Rett syndrome diagnostic criteria: lessons from the Natural History Study. Ann Neurol 2010;68:951-955.
8. Jellinger K, Armstrong D, Zoghbi HY, Percy AK. Neuropathology of Rett syndrome. Acta Neuropathol 1988;76:142-158.
9. Armstrong DD. The neuropathology of Rett syndrome—overview 1994. Neuropediatrics 1995;26:100-104.
10. Armstrong DD. Neuropathology of Rett syndrome. J Child Neurol 2005;20:747-753.
11. Zoghbi HY, Percy AK, Schultz RJ, Fill C. Patterns of X chromosome inactivation in the Rett syndrome. Brain Dev 1990;12:131-135.
12. Schanen NC, Dahle EJ, Capozzoli F, Holm VA, Zoghbi HY, Francke U. A new Rett syndrome family consistent with X-linked inheritance expands the X chromosome exclusion map. Am J Hum Genet 1997;61:634-641.
13. Amir RE, Van den Veyver IB, Wan M, Tran CQ, Francke U, Zoghbi HY. Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat Genet 1999;23:185-188.
14. Chen RZ, Akbarian S, Tudor M, Jaenisch R. Deficiency of methyl-CpG binding protein-2 in CNS neurons results in a Rett-like phenotype in mice. Nat Genet 2001;27:327-331.
15. Guy J, Hendrich B, Holmes M, Martin JE, Bird A. A mouse Mecp2-null mutation causes neurological symptoms that mimic Rett syndrome. Nat Genet 2001;27:322-326.
16. Shahbazian M, Young J, Yuva-Paylor L, et al. Mice with truncated MeCP2 recapitulate many Rett syndrome features and display hyperacetylation of histone H3. Neuron 2002;35:243-254.
17. Guy J, Gan J, Selfridge J, Cobb S, Bird A. Reversal of neurological defects in a mouse model of Rett syndrome. Science 2007;315:1143-1147.
18. Witt-Engerstrom I, Hagberg B. The Rett syndrome: gross motor disability and neural impairment in adults. Brain Dev 1990;12:23-26.
19. Engerstrom IW. Rett syndrome: the late infantile regression period--a retrospective analysis of 91 cases. Acta Pediatr 1992;81:167-172.
20. Clarke A. Rett syndrome. J Med Genet 1996;33:693-699.
21. Leonard H. Rett syndrome in Australia. University of Western Australia, Perth, Western Australia, 1996.
22. Laurvick CL, de Klerk N, Bower C, et al. Rett syndrome in Australia: a review of the epidemiology. J Pediatr 2006;148:347-352.
23. Einspieler C, Kerr AM, Prechtl HF. Is the early development of girls with Rett disorder really normal? Pediatr Res 2005;57:696-700.
24. Marschik PB, Kaufmann WE, Sigafoos J, et al. Changing the perspective on early development of Rett syndrome. Res Develop Disabil 2013;34:1236-1239.
25. Neul JL, Lane JB, Lee HS, et al. Developmental delay in Rett syndrome: data from the natural history study. J Neurodev Disord 2014;6:20.
26. Rett A. Rett syndrome. History and general overview. Am J Med Genet Suppl 1986;1:21-25.
27. Schultz RJ, Glaze DG, Motil KJ, et al. The pattern of growth failure in Rett syndrome. Am J Dis Child 1993;147:633-637.
28. Tarquinio DC, Motil KJ, Hou W, et al. Growth failure and outcome in Rett syndrome: Specific growth references. Neurology 2012;79:1653-1661.
29. Percy AK. Rett syndrome: exploring the autism link. Arch Neurol 2011;68:985-989.
30. Glaze DG, Schultz RJ, Frost JD. Rett syndrome: characterization of seizures versus non-seizures. Electroencephalogr Clin Neurophysiol 1998;106:79-83.
31. Glaze DG. Neurophysiology of Rett syndrome. J Child Neurol 2005;20:740-746.
32. Glaze DG, Percy AK, Skinner S, et al. Epilepsy and the natural history of Rett syndrome. Neurology 2010;74:909-912.
33. Lugaresi E, Cirignotta F, Montagna P. Abnormal breathing in the Rett syndrome. Brain Dev 1985;7:329-333.
34. Glaze DG, Frost JD, Jr., Zoghbi HY, Percy AK. Rett's syndrome. Correlation of electroencephalographic characteristics with clinical staging. Arch Neurol 1987;44:1053-1056.
35. Julu PO, Kerr AM, Apartopoulos F, et al. Characterisation of breathing and associated central autonomic dysfunction in the Rett disorder. Arch Dis Child 2001;85:29-37.
36. Motil KJ, Schultz RJ, Browning K, Trautwein L, Glaze DG. Oropharyngeal dysfunction and gastroesophageal dysmotility are present in girls and women with Rett syndrome. J Pediatr Gastroenterol Nutr 1999;29:31-37.
37. Motil KJ, Morrissey M, Caeg E, Barrish JO, Glaze DG. Gastrostomy placement improves height and weight gain in girls with Rett syndrome. J Pediatr Gastroenterol Nutr 2009;49:237-242.
38. Motil KJ, Caeg E, Barrish JO, et al. Gastrointestinal and nutritional problems occur frequently throughout life in girls and women with Rett syndrome. J Pediatr Gastroenterol Nutr 2012;55:292-298.
39. Leonard H, Ravikumara M, Baikie G, et al. Assessment and management of nutrition and growth in Rett syndrome. J Pediatr Gastroenterol Nutr 2013;57:451-460.
40. Schultz R, Glaze D, Motil K, Hebert D, Percy A. Hand and foot growth failure in Rett syndrome. J Child Neurol 1998;13:71-74.
41. Percy AK, Lee HS, Neul JL, et al. Profiling scoliosis in Rett syndrome. Pediatr Res 2010;67:435-439.
42. Neul JL, Fang P, Barrish J, et al. Specific mutations in methyl-CpG-binding protein 2 confer different severity in Rett syndrome. Neurology 2008;70:1313-1321.
43. Cuddapah VA, Pillai RB, Shekar KV, et al. Methyl-CpG-binding protein 2 (MECP2) mutation type is associated with disease severity in Rett syndrome. J Med Genet 2014;51:152-158.
44. Bebbington A, Anderson A, Ravine D, et al. Investigating genotype-phenotype relationships in Rett syndrome using an international data set. Neurology 2008;70:868-875.
45. LaSalle JM, Goldstine J, Balmer D, Greco CM. Quantitative localization of heterogeneous methyl-CpG-binding protein 2 (MeCP2) expression phenotypes in normal and Rett syndrome brain by laser scanning cytometry. Hum Mol Genet 2001;10:1729-1740.
46. Girard M, Couvert P, Carrie A, et al. Parental origin of de novo MECP2 mutations in Rett syndrome. Eur J Hum Genet 2001;9:231-236.
47. Trappe R, Laccone F, Cobilanschi J, et al. Mecp2 mutations in sporadic cases of rett syndrome are almost exclusively of paternal origin. Am J Hum Genet 2001;68:1093-1101.
48. Schanen C, Francke U. A severely affected male born into a Rett syndrome kindred supports X-linked inheritance and allows extension of the exclusion map. Am J Hum Genet 1998;63:267-269.
49. Augenstein K, Lane JB, Horton A, Schanen C, Percy AK. Variable phenotypic expression of a MECP2 mutation in a family. J Neurodev Disord 2009;1:313.
50. Kankirawatana P, Leonard H, Ellaway C, et al. Early progressive encephalopathy in boys and MECP2 mutations. Neurology 2006;67:164-166.
51. Salomao Schwartzman J, Zatz M, dos Reis Vasquez L, et al. Rett syndrome in a boy with a 47,XXY karyotype. Am J Hum Genet 1999;64:1781-1785.
52. Hoffbuhr K, Devaney JM, LaFleur B, et al. MeCP2 mutations in children with and without the phenotype of Rett syndrome. Neurology 2001;56:1486-1495.
53. Leonard H, Silberstein J, Falk R, et al. Occurrence of Rett syndrome in boys. J Child Neurol 2001;16:333-338.
54. Vorsanova SG, Yurov YB, Ulas VY, et al. Cytogenetic and molecular-cytogenetic studies of Rett syndrome (RTT): a retrospective analysis of a Russian cohort of RTT patients (the investigation of 57 girls and three boys). Brain Dev 2001;23(Suppl. 1):S196-S201.
55. Clayton-Smith J, Watson P, Ramsden S, Black GC. Somatic mutation in MECP2 as a non-fatal neurodevelopmental disorder in males. Lancet 2000;356:830-832.
56. Borg I, Freude K, Kubart S, et al. Disruption of Netrin G1 by a balanced chromosome translocation in a girl with Rett syndrome. Eur J Hum Genet 2005;13:921-927.
57. Archer HL, Evans JC, Millar DS, et al. NTNG1 mutations are a rare cause of Rett syndrome. Am J Med Genet A 2006;140:691-694.
58. White R, Ho G, Schmidt S, et al. Cyclin-dependent kinase-like 5 (CDKL5) mutation screening in Rett syndrome and related disorders. Twin Res Hum Genet 2010;13:168-178.
59. Pini G, Bigoni S, Engerstrom IW, et al. Variant of Rett syndrome and CDKL5 gene: clinical and autonomic description of 10 cases. Neuropediatrics 2012;43:37-43.
60. Hagebeuk EE, van den Bossche RA, de Weerd AW. Respiratory and sleep disorders in female children with atypical Rett syndrome caused by mutations in the CDKL5 gene. Dev Med Child Neurol 2013;55:480-484.
61. Katz DM, Berger-Sweeney JE, Eubanks JH, et al. Preclinical research in Rett syndrome: setting the foundation for translational success. Dis Model Mech 2012;5:733-745.
62. Lane JB, Lee HS, Smith LW, et al. Clinical severity and quality of life in children and adolescents with Rett syndrome. Neurology 2011;77:1812-1818.
63. Cobb S, Guy J, Bird A. Reversibility of functional deficits in experimental models of Rett syndrome. Biochem Soc Trans 2010;38:498-506.
64. Gadalla KK, Bailey ME, Cobb SR. MeCP2 and Rett syndrome: reversibility and potential avenues for therapy. Biochem J 2011;439:1-14.
65. Chapleau CA, Lane J, Larimore J, Li W, Pozzo-Miller L, Percy AK. Recent progress in Rett syndrome and MeCP2 dysfunction: assessment of potential treatment options. Future Neurol 2013;8.
66. Giacometti E, Luikenhuis S, Beard C, Jaenisch R. Partial rescue of MeCP2 deficiency by postnatal activation of MeCP2. Proc Natl Acad Sci U S A 2007;104:1931-1936.
67. Gadalla KK, Bailey ME, Spike RC, et al. Improved survival and reduced phenotypic severity following AAV9/MECP2 gene transfer to neonatal and juvenile male Mecp2 knockout mice. Mol Ther 2013;21:18-30.
68. Garg SK, Lioy DT, Cheval H, et al. Systemic delivery of MeCP2 rescues behavioral and cellular deficits in female mouse models of Rett syndrome. J Neurosci 2013;33:13612-13620.
69. Brendel C, Belakhov V, Werner H, et al. Readthrough of nonsense mutations in Rett syndrome: evaluation of novel aminoglycosides and generation of a new mouse model. J Mol Med 2011;89:389-398.
70. Schanen C, Houwink EJ, Dorrani N, et al. Phenotypic manifestations of MECP2 mutations in classical and atypical Rett syndrome. Am J Med Genet A 2004;126A:129-140.
71. Percy AK, Lane JB, Childers J, et al. Rett syndrome: North American database. J Child Neurol 2007;22:1338-1341.
72. Zingman LV, Park S, Olson TM, Alekseev AE, Terzic A. Aminoglycoside-induced translational read-through in disease: overcoming nonsense mutations by pharmacogenetic therapy. Clin Pharmacol Ther 2007;81:99-103.
73. Popescu AC, Sidorova E, Zhang G, Eubanks JH. Aminoglycoside-mediated partial suppression of MECP2 nonsense mutations responsible for Rett syndrome in vitro. J Neurosci Res 2010;88:2316-2324.
74. Pitcher MR, Herrera JA, Buffington SA, et al. Rett syndrome like phenotypes in the R255X Mecp2 mutant mouse are rescued by MECP2 transgene. Hum Mol Genet 2015 Jan 29 [Epub ahead of print].
75. Marchetto MC, Carromeu C, Acab A, et al. A model for neural development and treatment of Rett syndrome using human induced pluripotent stem cells. Cell 2010;143:527-539.
76. Chen WG, Chang Q, Lin Y, et al. Derepression of BDNF transcription involves calcium-dependent phosphorylation of MeCP2. Science 2003;302:885-889.
77. Martinowich K, Hattori D, Wu H, et al. DNA methylation-related chromatin remodeling in activity-dependent BDNF gene regulation. Science 2003;302:890-893.
78. Park H, Poo MM. Neurotrophin regulation of neural circuit development and function. Nat Rev Neurosci 2013;14:7-23.
79. Katz DM. Brain-derived neurotrophic factor and Rett syndrome. Handb Exp Pharmacol 2014;220:481-495.
80. Li W, Pozzo-Miller L. BDNF deregulation in Rett syndrome. Neuropharmacology 2014;76:737-746.
81. Chang Q, Khare G, Dani V, Nelson S, Jaenisch R. The disease progression of mecp2 mutant mice is affected by the level of BDNF expression. Neuron 2006;49:341-348.
82. Larimore JL, Chapleau CA, Kudo S, Theibert A, Percy AK, Pozzo-Miller L. Bdnf overexpression in hippocampal neurons prevents dendritic atrophy caused by Rett-associated MECP2 mutations. Neurobiol Dis 2009;34:199-211.
83. Deogracias R, Yazdani M, Dekkers MP, et al. Fingolimod, a sphingosine-1 phosphate receptor modulator, increases BDNF levels and improves symptoms of a mouse model of Rett syndrome. Proc Natl Acad Sci U S A 2012;109:14230-14235.
84. Ziemssen T, Kumpfel T, Klinkert WE, Neuhaus O, Hohlfeld R. Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. Brain-derived neurotrophic factor. Brain 2002;125:2381-2391.
85. Lauterborn JC, Lynch G, Vanderklish P, Arai A, Gall CM. Positive modulation of AMPA receptors increases neurotrophin expression by hippocampal and cortical neurons. J Neurosci 2000;20:8-21.
86. Ogier M, Wang H, Hong E, Wang Q, Greenberg ME, Katz DM. Brain-derived neurotrophic factor expression and respiratory function improve after ampakine treatment in a mouse model of Rett syndrome. J Neurosci 2007;27:10912-10917.
87. Massa SM, Yang T, Xie Y, et al. Small molecule BDNF mimetics activate TrkB signaling and prevent neuronal degeneration in rodents. J Clin Invest 2010;120:1774-1785.
88. Schmid DA, Yang T, Ogier M, et al. A TrkB small molecule partial agonist rescues TrkB phosphorylation deficits and improves respiratory function in a mouse model of Rett syndrome. J Neurosci 2012;32:1803-1810.
89. Kron M, Lang M, Adams IT, Sceniak M, Longo F, Katz DM. A BDNF loop-domain mimetic acutely reverses spontaneous apneas and respiratory abnormalities during behavioral arousal in a mouse model of Rett syndrome. Dis Model Mech 2014;7:1047-1055.
90. Borrell-Pages M, Canals JM, Cordelieres FP, et al. Cystamine and cysteamine increase brain levels of BDNF in Huntington disease via HSJ1b and transglutaminase. J Clin Invest 2006;116:1410-1424.
91. Zheng WH, Quirion R. Comparative signaling pathways of insulin-like growth factor-1 and brain-derived neurotrophic factor in hippocampal neurons and the role of the PI3 kinase pathway in cell survival. J Neurochem 2004;89:844-852.
92. Tropea D, Giacometti E, Wilson NR, et al. Partial reversal of Rett Syndrome-like symptoms in MeCP2 mutant mice. Proc Natl Acad Sci U S A 2009;106:2029-2034.
93. Castro J, Garcia RI, Kwok S, et al. Functional recovery with recombinant human IGF1 treatment in a mouse model of Rett Syndrome. Proc Natl Acad Sci U S A 2014;111:9941-9946.
94. Pitcher MR, Ward CS, Arvide EM, et al. Insulinotropic treatments exacerbate metabolic syndrome in mice lacking MeCP2 function. Hum Mol Genet 2013;22:2626-2633.
95. Corvin AP, Molinos I, Little G, et al. Insulin-like growth factor 1 (IGF1) and its active peptide (1-3)IGF1 enhance the expression of synaptic markers in neuronal circuits through different cellular mechanisms. Neurosci Lett 2012;520:51-56.
96. Khwaja OS, Ho E, Barnes KV, et al. Safety, pharmacokinetics, and preliminary assessment of efficacy of mecasermin (recombinant human IGF-1) for the treatment of Rett syndrome. Proc Natl Acad Sci U S A 2014;111:4596-4601.
97. Brucke T, Sofic E, Killian W, Rett A, Riederer P. Reduced concentrations and increased metabolism of biogenic amines in a single case of Rett-syndrome: a postmortem brain study. J Neural Transm 1987;68:315-324.
98. Lekman A, Witt-Engerstrom I, Gottfries J, Hagberg BA, Percy AK, Svennerholm L. Rett syndrome: biogenic amines and metabolites in postmortem brain. Pediatr Neurol 1989;5:357-362.
99. Roux JC, Dura E, Villard L. Tyrosine hydroxylase deficit in the chemoafferent and the sympathoadrenergic pathways of the Mecp2 deficient mouse. Neurosci Lett 2008;447:82-86.
100. Samaco RC, Mandel-Brehm C, Chao HT, et al. Loss of MeCP2 in aminergic neurons causes cell-autonomous defects in neurotransmitter synthesis and specific behavioral abnormalities. Proc Natl Acad Sci U S A 2009;106:21966-21971.
101. Roux JC, Dura E, Moncla A, Mancini J, Villard L. Treatment with desipramine improves breathing and survival in a mouse model for Rett syndrome. Eur J Neurosci 2007;25:1915-1922.
102. Zanella S, Mebarek S, Lajard AM, Picard N, Dutschmann M, Hilaire G. Oral treatment with desipramine improves breathing and life span in Rett syndrome mouse model. Respir Physiol Neurobiol 2008;160:116-121.
103. McEwen BS, Chattarji S, Diamond DM, et al. The neurobiological properties of tianeptine (Stablon): from monoamine hypothesis to glutamatergic modulation. Mol Psychiatry 2010;15:237-249.
104. Abdala AP, Lioy DT, Garg SK, Knopp SJ, Paton JF, Bissonnette JM. Effect of Sarizotan, a 5-HT1a and D2-like receptor agonist, on respiration in three mouse models of Rett syndrome. Am J Respir Cell Mol Biol 2014;50:1031-1039.
105. Maliszewska-Cyna E, Bawa D, Eubanks JH. Diminished prevalence but preserved synaptic distribution of N-methyl-d-aspartate receptor subunits in the methyl CpG binding protein 2(MeCP2)-null mouse brain. Neuroscience 2010;168:624-632.
106. Zhang ZW, Zak JD, Liu H. MeCP2 is required for normal development of GABAergic circuits in the thalamus. J Neurophysiol 2010;103:2470-2481.
107. Blue ME, Kaufmann WE, Bressler J, et al. Temporal and regional alterations in NMDA receptor expression in Mecp2-null mice. Anat Rec 2011;294:1624-1634.
108. Kron M, Howell CJ, Adams IT, et al. Brain activity mapping in Mecp2 mutant mice reveals functional deficits in forebrain circuits, including key nodes in the default mode network, that are reversed with ketamine treatment. J Neurosci 2012;32:13860-13872.
109. Durand S, Patrizi A, Quast KB, et al. NMDA receptor regulation prevents regression of visual cortical function in the absence of Mecp2. Neuron 2012;76:1078-1090.
110. Chao HT, Chen H, Samaco RC, et al. Dysfunction in GABA signalling mediates autism-like stereotypies and Rett syndrome phenotypes. Nature 2010;468:263-269.
111. Connelly JF. Vigabatrin. Ann Pharmacother 1993;27:197-204.
112. De Felice C, Signorini C, Leoncini S, et al. The role of oxidative stress in Rett syndrome: an overview. Ann N Y Acad Sci 2012;1259:121-135.